Search
Olopatadine
go.drugbank.com/drugs/DB00768ApprovedAn ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [L6790] Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions.
Products: TQ OLOFTAL® 0.2% SOLUCION OFTALMICAMoxifloxacin
go.drugbank.com/drugs/DB00218ApprovedInvestigationalBayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Mixtures: TQ OFTAMOX D UD®, TQ OFTAMOX® D UDProducts: T & B, TQ OFTAMOX® UDBoserolimab
go.drugbank.com/drugs/DB17452InvestigationalSynonyms: Immunoglobulin G1-kappa, anti-(homo sapiens CD27 (TNFRSF7, tumor necrosis factor receptor (TNFR) superfamily member 7))Etoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalAccumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Products: VP-TEC, EPOSIN CONCENTRADO PARA SOLUCION DE INFUSION DE 20 MG/MLHistamine H1 Receptor Activation
smpdb.ca/view/SMP0063452SignalingThis results in the dissociation of a Gαq-GTP monomer and a Gβγ dimer from the receptor . … Upon binding by histamine, the H1 receptor allosterically activates the G-protein by exchanging GDP for GTP at the G-protein's alpha subunit (Gαq).
Drugs: CalciumEnzymes: Histamine H1 receptor, Inositol 1,4,5-trisphosphate receptor type 1Vonlerolizumab
go.drugbank.com/drugs/DB16352InvestigationalVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Ar...
Synonyms: Immunoglobulin g1-kappa, anti-(human tumor necrosis factor receptor superfamily member 4 (act35 antigen, ox40l receptor, cd134 antigen))humanized mouse monoclonal antibody: .gamma.1 heavy chain (1-447), Immunoglobulin g1-kappa, anti-(homo sapiens tnfrsf4(tumor necrosis factor receptor (tnfr) superfamily member 4, act35, ox40, cd134)), humanized monoclonal antibodyNifedipine
go.drugbank.com/drugs/DB01115ApprovedInvestigational[A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383] … Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].
Mixtures: NIF TEN 50, NIF-TEN CAPSULEProducts: NIFEDIPIN AL T 20 RETARD, NIFEDIPIN RATIO20MG/ML TRAnti-CD7 CAR T-cell therapy
go.drugbank.com/drugs/DB18128ExperimentalSynonyms: A chimeric antigen receptor (CAR) immunotherapy directed against the target protein CD7, Anti-CD7 CAR T-cell therapyClotrimazole
go.drugbank.com/drugs/DB00257ApprovedInvestigationalVet approvedThe minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as … Clotrimazole's antimycotic properties were discovered in the late 1960s [A174094].
Mixtures: FITODERM TCProducts: TM-Clotrimazole, Kerasal foot and toe